Example: Heart Attack

Clinical Trials Sponsored by Elan Pharmaceuticals

Total 41 results

NCT01318421

Terminated

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT01144351

Terminated

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT00076544

Completed

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

Conditions: Pain
NCT00055484

Completed

A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache

Conditions: Migraine Headache
NCT00047749

Completed

Prialt (Ziconotide) In Severe Chronic Pain

Conditions: Pain
NCT00047580

Completed

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

Conditions: Multiple Sclerosis; Muscle Spasticity; Spinal Cord Injury; Stroke
NCT00047567

Terminated

Open-label Adjunctive Zonisamide for Bipolar Disorder

Conditions: Bipolar Disorders
NCT01791725

Completed

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Conditions: Down Syndrome
NCT01766336

Terminated

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Conditions: Alzheimer's Disease
NCT01735630

Completed

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Conditions: Alzheimer's Disease
NCT01674010

Terminated

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Conditions: Bipolar 1 Disorder
NCT01211665

Terminated

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)

Conditions: Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal
NCT01071083

Completed

Treatment Interruption of Natalizumab

Conditions: Relapsing Remitting Multiple Sclerosis
NCT01058005

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Conditions: Relapsing Remitting Multiple Sclerosis
NCT00871780

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
NCT00831649

Terminated

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Conditions: Rheumatoid Arthritis
NCT00801125

Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Conditions: Crohn's Disease
NCT00746941

Terminated

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Conditions: Progressive Multifocal Leukoencephalopathy
NCT00744679

Completed

A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

Conditions: Multiple Sclerosis
NCT00618267

Completed

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

Conditions: Multiple Sclerosis
NCT00559702

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Conditions: Relapsing-Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
NCT00516893

Completed

Natalizumab High Titer Immunogenicity and Safety

Conditions: Multiple Sclerosis
NCT00472992

Completed

Pregnancy Exposure Registry for Tysabri®

Conditions: Crohn's Disease; Prenatal Exposure; Multiple Sclerosis; Pregnancy
NCT00464074

Completed

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

Conditions: Multiple Sclerosis
NCT00358202

Completed

Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

Conditions: Pneumonia